<DOC>
	<DOCNO>NCT00228189</DOCNO>
	<brief_summary>Dendritic cell ( DCs ) professional antigen-presenting cell immune system . As currently use clinical vaccination protocol cancer patient . We evaluate ability mature DCs pulse carcinoembryonic antigen ( CEA ) -peptide ( arm A ) electroporated CEA-mRNA ( arm B ) induce CEA-specific T cell responses patient resectable liver metastasis colorectal cancer . To evaluate immune response , CEA-specific T cell reactivity monitor peripheral blood , resect abdominal lymph node , tumor tissue biopsy vaccination sit post-treatment DTH skin test . Patients vaccinate intradermally intravenously CEA-peptide pulsed mature DCs three time prior resection liver metastasis . In 2007 side-study add ( arm C ) , patient stage III high-risk stage II colorectal cancer amenable standard adjuvant oxaliplatin/capecitabine therapy vaccinate CEApeptide-pulsed DCs . Also group , safety immune response peripheral blood DTH-skin test primary endpoint . Results compare result obtain arm A .</brief_summary>
	<brief_title>Carcinoembryonic Antigen-loaded Dendritic Cells Advanced Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>For arm A B 1 . Histological document evidence colorectal cancer . 2 . Primary tumor surgically remove , recurrence ( ) liver . 3 . Planned surgical excision liver metastasis . 4 . HLAA2.1 phenotype accord lymphocyte HLA typing . 5 . Expression CEA primary tumor . 6 . ECOG performance status 01 , life expectancy &gt; 3 month . 7 . Age 1875 year . 8 . WBC &gt; 3.0 x 109/l , lymphocytes &gt; 0.8 x 109/l , platelet &gt; 100 x 109/l , serum creatinine &lt; 150 μmol/l , serum bilirubin &lt; 25 μmol/l . 9 . Expected adequacy followup . 10 . Written informed consent . 1 . Clinical sign extra hepatic metastasis , patient clinical suspicion metastases diagnostic test perform exclude . 2 . Prior chemotherapy , immunotherapy , radiotherapy within three month plan surgical excision allow . 3 . A history myocardial infarction , angina pectoris , cardiac arrhythmia , cerebrovascular accident , transient ischemic attack severe hypertension ( exclusion criterion autologous blood donation ) 4 . Concomitant use corticosteroid immunosuppressive agent . 5 . A history second malignancy past five year exclude adequately treat basal carcinoma skin carcinoma situ cervix . 6 . Serious concomitant disease , active infection . Specifically , patient autoimmune disease organ allografts patient history HBsAg HIV exclude . 7 . A known allergy shell fish . 8 . Pregnant lactating woman . For arm C ( sidestudy ) inclusion criterion : 1. histological proof colorectal cancer 2 . HLAA0201 positive 3. stage III ( T14N12M0 ) cancer high risk stage II ( T4 and/or poor differentiation histology and/or perforation and/or obstruction and/or venous invasion and/or histological analysis ≤10 lymph node ) 4 . ≤ 8 week since surgical resection primary colorectal tumor 5 . Age 1875 year 6. WHO performance 01 ( Karnofsky 10070 % ) 7 . WBC ≥ 3.0x109/l 8 . Platelets ≥ 100x109/l 9 . Hb ≥ 6 mmol/l 10 . Total bilirubin ≤ 2x UNL 11 . ASAT ALAT ≤ 3x UNL 12 . Serum creatinine ≤ 1.5 x UNL 13 . Expected adequacy followup 14 . Signed write informed consent exclusion criterion 1 . A history second malignancy within last 5 year . Adequately treat basal carcino¬ma skin carcinoma situ cervix acceptable within period 2 . Serious concomitant disease . Autoimmune disease organ graft . 3 . Other serious concomitant disease prevent safe administration study drug likely interfere study assessment . 4 . A known allergy shell fish ( contain KLH ) 5 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Dendritic cell</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Carcinoembryonic antigen</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>